Studies on PIK3CA mutations and tumor lipid metabolism reveal that the PIK3CA-E545K mutation promotes nuclear accumulation of SREBP1, enhancing transcription of apolipoprotein A5 (APOA5) and thereby mediating platinum-based drug resistance in CRC (84). This evidence concerns the gene APOA5 and neoplasm.